Influence of carrier protein conjugation site and terminal modification of a GnRH-I peptide sequence in the development of a highly specific anti-fertility vaccine part I

Ferro, V.A. and Khan, M.A. and Earl, E.R. and Harvey, M.J. and Colston, A. and Stimson, W.H. (2002) Influence of carrier protein conjugation site and terminal modification of a GnRH-I peptide sequence in the development of a highly specific anti-fertility vaccine part I. American Journal of Reproductive Immunology, 48 (6). pp. 361-371. ISSN 1600-0897 (https://doi.org/10.1034/j.1600-0897.2002.01120.x)

Full text not available in this repository.Request a copy

Abstract

PROBLEM: We previously immunoneutralized gonadotrophin releasing hormone (GnRH), using an analogue of GnRH (des-1 GnRH-1), conjugated to tetanus toxoid via a carbodiimide reaction. The castration effect on the reproductive system was not consistent in all the treated animals. Therefore, we examined the possibility that conjugation to the carrier protein via the N- or C-terminal could have an effect on efficacy. METHOD OF STUDY: GnRH analogue sequences were synthesized consisting of an additional cysteine at either terminal and specific conjugation was carried out using a bifunctional linker agent. RESULTS: Conjugation of the monomer through the N-terminal proved to be a highly effective means of causing immunocastration in terms of decreased gonadotrophin and testosterone concentrations and testicular size, whereas conjugation through the C-terminal proved to be ineffective. This was reflected in the ability of the antibodies to bind native GnRH, but not the levels of the anti-GnRH antibodies. CONCLUSION: Immunoneutralization efficacy was attributed to the importance of preserving the GnRH C-terminal.

ORCID iDs

Ferro, V.A. ORCID logoORCID: https://orcid.org/0000-0003-1967-3603, Khan, M.A., Earl, E.R., Harvey, M.J., Colston, A. and Stimson, W.H.;